BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rump JA, Schönborn H. [Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment]. Z Rheumatol. 2010;69:903-909. [PMID: 20532789 DOI: 10.1007/s00393-010-0652-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Fischer-Betz RE, Schneider M. [Biologics during pregnancy and breast--feeding]. Z Rheumatol 2010;69:780-7. [PMID: 21063826 DOI: 10.1007/s00393-010-0640-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
2 Garip Y. Use of biologic agents for rheumatic diseases in pregnancy. World J Rheumatol 2015; 5(2): 50-58 [DOI: 10.5499/wjr.v5.i2.50] [Reference Citation Analysis]
3 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Gogia M, Furst DE. Rheumatoid arthritis and pregnancy: Disease activity, pregnancy outcomes, and treatment options during pregnancy and lactation. Drug Dev Res 2011;72:689-702. [DOI: 10.1002/ddr.20478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84. [PMID: 24284028 DOI: 10.1016/j.reprotox.2013.11.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
6 Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, Salas-Heredia E, Sánchez-Barrioluengo M, Barber X, Rosas J; AIRE-MB group. Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence 2013;7:961-72. [PMID: 24101863 DOI: 10.2147/PPA.S33109] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
7 Hazes JM, Coulie PG, Geenen V, Vermeire S, Carbonnel F, Louis E, Masson P, De Keyser F. Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use. Rheumatology (Oxford). 2011;50:1955-1968. [PMID: 21890617 DOI: 10.1093/rheumatology/ker302] [Cited by in Crossref: 80] [Cited by in F6Publishing: 60] [Article Influence: 8.0] [Reference Citation Analysis]
8 Abdolmohammadi-vahid S, Danaii S, Hamdi K, Jadidi-niaragh F, Ahmadi M, Yousefi M. Novel immunotherapeutic approaches for treatment of infertility. Biomedicine & Pharmacotherapy 2016;84:1449-59. [DOI: 10.1016/j.biopha.2016.10.062] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
9 Abrouk M, Beroukhim K, Nakamura M, Zhu TH, Farahnik B, Singh R, Lee K, Koo J, Bhutani T. Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule. Int J Womens Dermatol 2017;3:S67-9. [PMID: 28492043 DOI: 10.1016/j.ijwd.2017.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient. Journal of the American Academy of Dermatology 2019;80:43-53. [DOI: 10.1016/j.jaad.2018.06.056] [Cited by in Crossref: 119] [Cited by in F6Publishing: 92] [Article Influence: 59.5] [Reference Citation Analysis]
11 Chambers CD, Johnson DL. Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy. Birth Defects Research Part A: Clinical and Molecular Teratology 2012;94:607-11. [DOI: 10.1002/bdra.23033] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
12 Babalola O, Strober BE. Management of psoriasis in pregnancy: Treatment of cutaneous disorders of pregnancy. Dermatol Ther 2013;26:285-92. [DOI: 10.1111/dth.12073] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
13 Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Review of Clinical Immunology 2015;11:709-20. [DOI: 10.1586/1744666x.2015.1037742] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Bae YC, Van Voorhees AS, Hsu S, Korman NJ, Lebwohl MG, Young M, Bebo B, Kimball AB. Review of treatment options for psoriasis in pregnant or lactating women: From the Medical Board of the National Psoriasis Foundation. Journal of the American Academy of Dermatology 2012;67:459-77. [DOI: 10.1016/j.jaad.2011.07.039] [Cited by in Crossref: 73] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]